Quotes

Company Overview

Financial Analysis

Main Composition Key Indicators Financial Statement

Multi-dimentional Analyses

Company Valuation Capital Tracking Short Selling Data

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company’s lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

CEO： Countouriotis M.D., Athena Maria

Market： NASDAQ

Hot List

TradeSearchNews

SymbolLatest price%Chg

Moomoo > Quotes > TPTX Turning Point Therapeutics > Detailed Quotes

TPTX Turning Point Therapeutics

36.740+1.380+3.90%

Close 05/20 20:00 ET

36.74000.00%

Post Mkt Price 05/20 16:00 ET

High

38.000

Open

36.250

Turnover

22.48M

Low

34.480

Pre Close

35.360

Volume

621.45K

Post-Market

Price Forecast

No Data

TPTX Turning Point Therapeutics

News

Comment

News

Announcement

All

Earnings Report

Related Transactions

Changes In Ownership

Major Events

Other